Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on nitric oxide (NO) solutions, has announced its upcoming fiscal third quarter 2025 financial results conference call. The company will release its financial results for the period ended December 31, 2024, on Monday, February 10, 2025, after market close.
The conference call will be held at 4:30 PM ET on the same day, with domestic and international dial-in numbers available. A webcast of the conference call will be accessible through the Events section of the company's website, with a replay available online after the call.
Beyond Air (NASDAQ: XAIR), un'azienda biotech e dispositivi medici in fase commerciale focalizzata sulle soluzioni di ossido nitrico (NO), ha annunciato la sua prossima conferenza stampa sui risultati finanziari del terzo trimestre fiscale 2025. L'azienda pubblicherà i risultati finanziari per il periodo conclusosi il 31 dicembre 2024, lunedì 10 febbraio 2025, dopo la chiusura del mercato.
La conferenza telefonica si terrà alle 16:30 ET nello stesso giorno, con numeri di accesso nazionali e internazionali disponibili. Una trasmissione in streaming della conferenza sarà accessibile attraverso la sezione Eventi del sito web dell'azienda, con una registrazione disponibile online dopo la chiamata.
Beyond Air (NASDAQ: XAIR), una empresa de dispositivos médicos y biotecnología en etapa comercial centrada en soluciones de óxido nítrico (NO), ha anunciado su próxima llamada de conferencia sobre resultados financieros del tercer trimestre fiscal 2025. La compañía publicará sus resultados financieros para el período finalizado el 31 de diciembre de 2024, el lunes 10 de febrero de 2025, después del cierre del mercado.
La llamada de conferencia se llevará a cabo a las 4:30 PM ET el mismo día, con números de acceso nacionales e internacionales disponibles. Una transmisión en vivo de la conferencia estará accesible a través de la sección de Eventos en el sitio web de la empresa, con una grabación disponible en línea después de la llamada.
비욘드 에어 (NASDAQ: XAIR), 질산 산화물(NO) 솔루션에 중점을 둔 상업 단계의 의료 기기 및 생명 공학 회사가 2025 회계 연도 제3 분기 재무 결과 발표 전화 회의를 예정하고 있다고 발표했습니다. 회사는 2024년 12월 31일로 종료된 기간에 대한 재무 결과를 2025년 2월 10일 월요일에 시장 마감 후 발표할 것입니다.
전화 회의는 같은 날 오후 4시 30분 ET에 열리며, 국내 및 국제 접속 번호가 제공됩니다. 회의의 웹캐스트는 회사 웹사이트의 이벤트 섹션을 통해 접근 가능하며, 통화 후에 온라인에서 다시보기 가능합니다.
Beyond Air (NASDAQ: XAIR), une entreprise de dispositifs médicaux et de biopharmaceutiques en phase commerciale axée sur les solutions d'oxyde nitrique (NO), a annoncé sa prochaine conférence téléphonique sur les résultats financiers du troisième trimestre fiscal 2025. L'entreprise publiera ses résultats financiers pour la période se terminant le 31 décembre 2024, le lundi 10 février 2025, après la clôture des marchés.
La conférence téléphonique aura lieu à 16h30 ET le même jour, avec des numéros d'appel nationaux et internationaux disponibles. Un webinaire de la conférence sera accessible via la section Événements du site internet de la société, avec un enregistrement disponible en ligne après l'appel.
Beyond Air (NASDAQ: XAIR), ein Unternehmen für medizinische Geräte und Biopharmazeutika in der kommerziellen Phase, das sich auf Lösungen mit Stickstoffmonoxid (NO) konzentriert, hat seine bevorstehende Telefonkonferenz zu den finanziellen Ergebnissen des dritten Quartals 2025 angekündigt. Das Unternehmen wird seine finanziellen Ergebnisse für den Zeitraum zum 31. Dezember 2024 am Montag, den 10. Februar 2025, nach Marktschluss veröffentlichen.
Die Telefonkonferenz findet am selben Tag um 16:30 Uhr ET statt, wobei nationale und internationale Zugangnummern zur Verfügung stehen. Ein Webcast der Telefonkonferenz wird über den Bereich Veranstaltungen auf der Unternehmenswebsite zugänglich sein, mit einer Online-Wiederholung nach dem Anruf.
- None.
- None.
GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the fiscal third quarter 2025 ended December 31, 2024 on Monday, February 10, 2025 after the market closes.
| Conference Call & Webcast | ||
| Monday, February 10th @ 4:30 PM ET | ||
| Domestic: | 1-877-407-0784 | |
| International: | 1-201-689-8560 | |
| Conference ID: | 13750714 | |
Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call.
About Beyond Air®, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
When will Beyond Air (XAIR) report its Q3 2025 earnings?
How can investors join Beyond Air's (XAIR) Q3 2025 earnings call?
What period will Beyond Air's (XAIR) Q3 2025 earnings cover?
Will there be a replay available for Beyond Air's (XAIR) Q3 2025 earnings call?
